The tumor patient in the COVID-19 pandemic–an interview-based study of 30 patients undergoing systemic antiproliferative therapy

Ulrich Kaiser(University of Applied Sciences Landshut), Florian Kaiser(University of Applied Sciences Landshut), Ana Hoffmann(University of Applied Sciences Landshut), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Jörg Schmidt(TU Dresden)

PLoS ONE

August 11, 2021

10.1371/journal.pone.0256047

Cited by 4

Related Papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2014|1.7k

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

|The Lancet Oncology|2016|417

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280